


BcnPit | XIV Biennial Conference

The future of research

Full scientific programme


May 13-15, 2026 | Hotel Porta Fira Barcelona

In-person conference and online broadcast



Wednesday, May 13, 2026

Track	Time	Session / Presentation	Chair / Speaker
Opening Session	11:30 - 11:45	Welcome	Ms. Miren Jone Gurrutxaga
Breaking News in AD	11:45 - 12:45	Chair: Prof. Mercè Boada, MD, PhD; Xavier Montalbán, MD, PhD	
	11:45	Next Challenges in Blood Biomarkers for Alzheimer's Disease	Laia Montoliu-Gaya, PhD
	12:05	Dementia Care in the Era of Neurotechnology	Álvaro Pascual-Leone, MD, PhD
	12:25	AI-based differential diagnosis of various dementias	Prof. Vijaya B. Kolachalama
Fragility	12:45 - 13:15	Chair: Prof. James Becker	
		Clinical approach for healthy longevity and brain health	Prof. Bruno Vellas, MD, PhD
	13:15 - 14:00	Lunch break	
Epidemiology	14:00 - 15:00	Chair: Agustín Ruiz, MD, PhD; Prof. Alfred Njamnshi	
	14:00	Developing sustainable research capacity for dementia in Africa: a BUILD-FSA and AI-BOND perspective	Bernard Fongang, PhD
	14:15	BRAIN's approach to building infrastructure for dementia research and care in Africa.	Yembe Njamnshi, MD, MSc
	14:30	Learnings from the MS world.	Xavier Montalbán, MD, PhD
Structural MRI	15:00 - 16:00	Chair: Eric Westman, PhD	
	15:00	Is the ATN framework one size fits all?	Prof. Ann D. Cohen
	15:15	MRI in monitoring Alzheimer's patients in the era of novel therapeutics	Prof. Nuria Bargalló, MD
	15:30	The Role of Structural MRI in Dementia Diagnosis	Álex Rovira, MD
	16:00 - 16:30	Coffee break	
AI	16:30 - 17:30	Chair: Josep M. Argimon, MD, PhD	
	16:30	Real world evidence generation from large medical databases	Joaquín Dopazo, PhD
	16:45	From words to biomarkers: leveraging AI and spontaneous speech in the Alzheimer's disease spectrum	Sergi Valero, PhD




17:00 Modeling Dementia via AI-enabled Patient Digital Twins

Stylios Kokkas

Ceremony 17:30 - 18:00 Lluís Tàrraga Award Ceremony

Thursday, May 14, 2026


Track	Time	Session / Presentation	Chair / Speaker
Biomarkers	09:00 - 10:00	Chair: Daniel Alcolea, MD, PhD	
	09:00	Blood-based biomarkers in the Alzheimer's continuum	Marc Suárez-Calvet, MD, PhD
	09:15	Real-world experience for the identification of patients at risk of AD with plasma biomarkers	Amanda Cano, PhD
	09:30	Connecting Alzheimer's disease with Aging.	Alfredo Ramírez, MD, PhD
	09:45	Plasma Abeta42/Abeta40 Identifies Early Amyloid Changes in PET Negative Individuals with Subjective Cognitive Decline	José Antonio Allué, PhD
PET	10:00 - 10:45	Chair: Jesús Silva, PhD	
	10:00	Implementation of the new NIA-AA diagnostic criteria for Alzheimer's disease with PET	Víctor L. Villemagne, MD
	10:45 - 11:15	Coffee break	
Omics	11:15 - 12:15	Chair: Victoria Fernández, PhD	
	11:15	High-Dimensional Proteomics for Neurodegeneration: From Blood Signatures to Mechanistic Insight in Alzheimer's and Related Dementias	Prof. Carlos Cruchaga
	11:30	Beyond Plasma: Progranulin Reveals a Brain-Specific Neuroimmune Network	Agustín Ruiz, MD, PhD
	11:45	Epigenomic studies in Dementia	Prof. Katie Lunnon
	12:00	Using omics to identify synaptotherapeutic targets	Johanna Jackson, PhD
Ceremony	12:15 - 12:30	Boada Rovira Award	
Neuroinflammation	12:30 - 13:00	Chair: Prof. Xavier Montalbán, MD, PhD	
	12:30	Innate Immunity - a future treatment target in Alzheimer's disease?	Prof. Michael Heneka, MD, PhD



Break	13:00 - 14:00	Lunch break	
New Diagnostic Era	14:00 - 15:00	Chair: Alberto Lleó, MD, PhD	
	14:15	Diagnostic Criteria and Absolute Risk of Impairment	Prof. Clifford R. Jack, Jr., MD
	14:20	The duality of diagnosis	Prof. Nikolaos Scarmeas, MD, PhD
Disease-Modifying Treatments	15:00 - 16:30	Chair: Prof. Xavier Montalbán, MD, PhD	
	15:00	Latest results and next development steps for trontinemab in Alzheimer's disease	Christopher Lane, MD, PhD
	15:30	Beyond clinical trials: early frontline experience with anti-amyloid therapies in Alzheimer's disease	Alma Ghirelli, MD José Soria, MD
	16:00	Evaluation and Treatment of Early Alzheimer's Disease with Anti Amyloid Monoclonal Antibody in Neurology Community Clinics (USA)	
	16:30 - 17:00	Coffee break	
New Treatment Strategies	17:00 - 18:00	Chair: Prof. Mercè Boada, MD, PhD	
	17:00	Valiltramiprosate Potentially First Oral Disease Modifying Treatment for Alzheimer's Patients with APOE4/4 Genotype	Martin Tolar, MD, PhD
	17:15	Therapeutic plasma exchange with Albumin Replacement: Real-World Data from a single center study	Antonio Páez, MD
	17:30	Topline results of a Phase IV trial of EGb 761 in patients with Mild Cognitive Impairment (ACE-2020-EGb 761)	Xavier Morató, PhD

Friday, May 15, 2026

Track	Time	Session / Presentation	Chair / Speaker
New Treatment Strategies	09:00 - 10:15	Chair: Pilar Sanz, MD, PhD	
	09:00	The Abeta disassembling compound PRI-002 does not cause ARIA in an ongoing phase 2 trial	Prof. Dieter Willbold



	09:15	Beyond the Lab: Real-World Implementation of Non Invasive Brain Stimulation in Cognitive Medicine	Francisco Mira, MD
	09:30	The Life's End Benefits of cannabidiol and tetrahydrocannabinol (LiBBY) Study	Prof. Jacobo Mintzer
	09:45	Sensory Neuromodulation for Alzheimer's Disease and Neuroprotection	Rosalind Firenze, PhD
Update on Vascular Dementia	10:15 - 10:45	Chair: Prof. Bengt Winblad, MD	
	10:30	Relationship between subclinical vascular disease and Alzheimer's disease pathology	Óscar López, MD
Break	10:45 - 11:15	Coffee break	
Neuropathology	11:15 - 12:00	Chair: Alberto Rábano, MD, PhD	
	11:15	Neuropathological findings in patients treated with anti-amyloid therapy	Milos Ikonomic, MD
	11:30	Deep phenotyping of PSEN1 E280A brains: a multiomic approach	Diego Sepúlveda
	11:45	Alzheimer's Disease Pathology: Lessons from Longitudinal Epidemiologic Cohorts	Margaret Flanagan, MD
Social Value of the Treatment	12:00 - 13:00	Chair: Josep Corbella	
	12:00	Roundtable	Prof. Mercè Boada, MD, PhD
Closing Session	13:00 - 13:30	Introduced by Ace Alzheimer Center Barcelona and University of Pittsburgh representatives	